Pathology of fatty liver disease (Q36814311)

16 August 2017

1 reference

title

Pathology of fatty liver disease (English)

1 reference

16 August 2017

0 references

1

Elizabeth M Brunt

1 reference

16 August 2017

1 February 2007

1 reference

16 August 2017

1 reference

16 August 2017

20 Suppl 1

1 reference

16 August 2017

S40-8

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.3800680

16 August 2017

0 references

cites work

Ethnic differences in the prevalence of cryptogenic cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Liver fibrosis in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Update on nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Nonalcoholic fatty liver disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Molecular virology of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Insulin resistance: a metabolic pathway to chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Steatosis: co-factor in other liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Histopathology of pediatric nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Novel endothelial cell markers in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Nonalcoholic steatohepatitis: an expanded clinical entity.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Chronic hepatitis C and superimposed nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Pathogenesis of steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Interaction of non-alcoholic fatty liver disease with other liver diseases.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Chronic hepatitis. An update on terminology and reporting.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

Alcoholic and nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800680

7 January 2021

10.1038/MODPATHOL.3800680

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17486051